NCT06922266Not yet recruiting
Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a monocentric prospective observational study. This study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 26 Mar 2025
- Start date
- 1 May 2025
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Ospedale San Raffaele
- Diseases
- Lung cancer
- NCT number
- NCT06922266
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 May 2025 to the primary completion date, 30 Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of any active infection or underlying condition that could compromise the safety of tissue and blood sampling.
- Prior history of another malignancy that might interfere with data interpretation related to non-small cell lung cancer progression and immune response.
- Any current use of immunosuppressive medications (e.g., high-dose steroids) which might alter immune response assessments, except as part of non-small cell lung cancer treatment.
Other
- Pregnancy and breastfeeding
Who the study is looking for
- Participant is willing and able to provide informed consent for participation in the study.
- Age: Adults aged 18 years or older.
- Diagnosis: non-small cell lung cancer (Stage I-II, III), with or without lymph node involvement, ideally with sufficient tumor burden to provide adequate tissue for analysis. In accordance with good clinical practice, patients with early-stage disease will undergo direct surgery, whereas patients with advanced-stage disease will receive neoadjuvant treatment followed by surgery.
- Ability to attend scheduled follow-up visits, if applicable, for additional peripheral blood sample collection during treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.